Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.68 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.32 |
| ▸ | CETP | P11597 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477633 | 0.86 | VDR (0.67) | VDRCETPALOX5 | |
| SCHEMBL2890399 | 0.83 | VDR (0.73) | VDRMAPTL3MBTL1 | |
| SCHEMBL4888601 | 0.83 | VDR (0.92) | VDRCETPS1PR1S1PR5ALOX5 | |
| SCHEMBL229168 | 0.81 | VDR (1.00) | VDRS1PR1S1PR5ALOX5 | |
| SCHEMBL4893153 | 0.80 | VDR (0.83) | VDRGABRA1GABRB2CETPALOX5 | |
| SCHEMBL6477462 | 0.80 | VDR (0.79) | VDRALOX5 | |
| SCHEMBL4881104 | 0.76 | VDR (0.77) | VDRFFAR4S1PR1S1PR5 | |
| SCHEMBL1022006 | 0.76 | VDR (0.61) | VDRMAPTTDP1L3MBTL1ALOX5 | |
| SCHEMBL4892728 | 0.75 | VDR (0.72) | VDRCETP | |
| SCHEMBL2641441 | 0.74 | VDR (0.84) | VDRFFAR4S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | claimed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | VDR 3/4885FFAR4 570/4885GABRA1 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.